版本:
中国

BRIEF-Soligenix says publication of phase 2 long-term follow-up results of SGX942

May 18 Soligenix Inc:

* Soligenix announces publication of its phase 2 long-term follow-up results of SGX942 for the treatment of oral mucositis in head and neck cancer patients

* Says SGX942 found to be safe and well tolerated with multiple potential ancillary benefits Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐